oral KRAS(G12C) inhibitor
ph. III candidate for NSCLC
from de novo SBDD in SWII pocket
Cancer Discov.
Novartis, Basel, CH
JDQ443
Context. JDQ443 (Novartis Institute for Biomedical Research) is an oral KRASG12C inhibitor being developed for various advanced solid tumors. Despite accounting for 85% of RAS oncogenic mutations in all…